0001209191-21-070646.txt : 20211220 0001209191-21-070646.hdr.sgml : 20211220 20211220184919 ACCESSION NUMBER: 0001209191-21-070646 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211217 FILED AS OF DATE: 20211220 DATE AS OF CHANGE: 20211220 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Patel Gautam CENTRAL INDEX KEY: 0001738054 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38485 FILM NUMBER: 211506400 MAIL ADDRESS: STREET 1: C/O AMNEAL PHARMACEUTICALS LLC STREET 2: 400 CROSSING BLVD CITY: BRIDGEWATER STATE: NJ ZIP: 08807 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Amneal Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001723128 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: BUSINESS PHONE: (908) 947-3120 MAIL ADDRESS: STREET 1: 400 CROSSING BOULEVARD STREET 2: 3RD FLOOR CITY: BRIDGEWATER STATE: NJ ZIP: 08807 FORMER COMPANY: FORMER CONFORMED NAME: Atlas Holdings, Inc. DATE OF NAME CHANGE: 20171117 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-12-17 0 0001723128 Amneal Pharmaceuticals, Inc. AMRX 0001738054 Patel Gautam C/O AMNEAL PHARMACEUTICALS, INC. 400 CROSSING BOULEVARD BRIDGEWATER NJ 08807 1 0 0 0 Class A Common Stock 2021-12-17 4 P 0 50000 4.21 A 258784 D Class A Common Stock 12887433 I See Footnote The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.14 to $4.35. The reporting person undertakes to provide Amneal Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or of the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. By trusts which the reporting person may be deemed to control. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. /s/ Meredith Cook, Attorney-in-Fact 2021-12-20